Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Offringa

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 18, 2001
Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus toleranceA T den Boer, L Diehl, G J van Mierlo, et al.
Cold Spring Harbor Symposia on Quantitative Biology|January 1, 1989
Immunosurveillance of virus-induced tumorsC J Melief, W L Vasmel, R Offringa, et al.
Human Immunology|March 1, 1997
Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA)E Ras, S H van der Burg, S T Zegveld, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 20, 2000
Adoptive T cell immunotherapy of human uveal melanoma targeting gp100R P Sutmuller, L R Schurmans, L M van Duivenvoorde, et al.
Science (New York, N.Y.)|March 7, 1998
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphismJ M den Haan, L M Meadows, W Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2001
Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumorsJ P Medema, J de Jong, L T Peltenburg, et al.
The Journal of Experimental Medicine|August 22, 2001
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyA van Elsas, R P Sutmuller, A A Hurwitz, et al.
The Journal of Experimental Medicine|July 6, 2000
Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuliD H Schuurhuis, S Laban, R E Toes, et al.
Gene Therapy|October 21, 2003
Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1M Ossevoort, B M J Visser, D J M van den Wollenberg, et al.
The Journal of Experimental Medicine|August 29, 1997
Tumor eradication by wild-type p53-specific cytotoxic T lymphocytesM P Vierboom, H W Nijman, R Offringa, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Journal of Immunology (Baltimore, Md. : 1950)|August 18, 2001
Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus toleranceA T den Boer, L Diehl, G J van Mierlo, et al.
Cold Spring Harbor Symposia on Quantitative Biology|January 1, 1989
Immunosurveillance of virus-induced tumorsC J Melief, W L Vasmel, R Offringa, et al.
Human Immunology|March 1, 1997
Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA)E Ras, S H van der Burg, S T Zegveld, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 20, 2000
Adoptive T cell immunotherapy of human uveal melanoma targeting gp100R P Sutmuller, L R Schurmans, L M van Duivenvoorde, et al.
Science (New York, N.Y.)|March 7, 1998
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphismJ M den Haan, L M Meadows, W Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2001
Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumorsJ P Medema, J de Jong, L T Peltenburg, et al.
The Journal of Experimental Medicine|August 22, 2001
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyA van Elsas, R P Sutmuller, A A Hurwitz, et al.
The Journal of Experimental Medicine|July 6, 2000
Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuliD H Schuurhuis, S Laban, R E Toes, et al.
Gene Therapy|October 21, 2003
Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1M Ossevoort, B M J Visser, D J M van den Wollenberg, et al.
The Journal of Experimental Medicine|August 29, 1997
Tumor eradication by wild-type p53-specific cytotoxic T lymphocytesM P Vierboom, H W Nijman, R Offringa, et al.
Pageof 10